WallStSmart

GE Vernova LLC (GEV)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE Vernova LLC generates 611% more annual revenue ($39.38B vs $5.54B). RMD leads profitability with a 27.4% profit margin vs 23.8%. RMD appears more attractively valued with a PEG of 1.23. RMD earns a higher WallStSmart Score of 73/100 (B).

GEV

Strong Buy

67

out of 100

Grade: B-

Growth: 8.0Profit: 7.0Value: 4.3Quality: 4.3
Piotroski: 4/9Altman Z: 1.02

RMD

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 5.3Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GEV.

RMDOvervalued (-13.1%)

Margin of Safety

-13.1%

Fair Value

$229.58

Current Price

$206.76

$22.82 premium

UndervaluedFair: $229.58Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GEV6 strengths · Avg: 9.2/10
Market CapQuality
$300.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
75.7%10/10

Every $100 of equity generates 76 in profit

EPS GrowthGrowth
1816.0%10/10

Earnings expanding 1816.0% YoY

Profit MarginProfitability
23.8%9/10

Keeps 24 of every $100 in revenue as profit

Revenue GrowthGrowth
16.3%8/10

16.3% revenue growth

Free Cash FlowQuality
$4.79B8/10

Generating 4.8B in free cash flow

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.3%10/10

Strong operational efficiency at 35.3%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.3%9/10

Every $100 of equity generates 25 in profit

Profit MarginProfitability
27.4%9/10

Keeps 27 of every $100 in revenue as profit

Areas to Watch

GEV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.864/10

Expensive relative to growth rate

P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
20.1x2/10

Trading at 20.1x book value

Altman Z-ScoreHealth
1.022/10

Distress zone — elevated risk

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : GEV

The strongest argument for GEV centers on Market Cap, Return on Equity, EPS Growth. Profitability is solid with margins at 23.8% and operating margin at 5.5%. Revenue growth of 16.3% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.4% and operating margin at 35.3%. Revenue growth of 10.8% demonstrates continued momentum.

Bear Case : GEV

The primary concerns for GEV are PEG Ratio, P/E Ratio, Price/Book.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

GEV profiles as a growth stock while RMD is a mature play — different risk/reward profiles.

GEV carries more volatility with a beta of 1.31 — expect wider price swings.

GEV is growing revenue faster at 16.3% — sustainability is the question.

GEV generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

RMD scores higher overall (73/100 vs 67/100), backed by strong 27.4% margins and 10.8% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GE Vernova LLC

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

GE Vernova LLC, an energy business company, generates electricity.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?